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Bedaquiline Microheteroresistance after Cessation  
of Tuberculosis Treatment
To the Editor: Bedaquiline improves survival 
among persons with multidrug-resistant tuber-
culosis (MDR-TB).1 We report the case of a 
65-year-old South African man who was negative 
for human immunodeficiency virus and in whom 
MDR-TB was diagnosed in 2013 (resistant to ri-
fampin and isoniazid; phenotypically susceptible 
to a fluoroquinolone and amikacin). A baseline 
radiograph showed changes consistent with bi-
lateral tuberculosis with left apex cavitation. He 
started standardized treatment that included 
moxifloxacin, pyrazinamide, kanamycin, ethiona-
mide, isoniazid, and terizidone. After initial spu-
tum culture conversion (at month 3) and clinical 
improvement, the patient again became culture-
positive, and bilateral cavitation developed. After 
detection of phenotypic resistance to fluoroqui-
nolones (at month 6), his treatment was revised 
(at month 8) to include high-dose isoniazid, 
ethambutol, pyrazinamide, terizidone, linezolid, 
paraaminosalicylic acid, and kanamycin (Fig. 1 and 
the Supplementary Appendix, available with the 
full text of this letter at NEJM.org). Bedaquiline 
was added 22 days later and was administered 
for 6 months.2 The patient remained culture-
positive (treatment failure), and treatment was 
stopped 15 months after revision of the regimen. 
The patient died 7 months later.
Overall, eight Mycobacterium tuberculosis isolates 
(A through H) were assessed by means of whole-
genome sequencing, targeted deep sequencing3 
of Rv0678, and phenotypic bedaquiline resistance 
testing. Whole-genome sequencing of isolate A, 
which was obtained 4.7 months after the initia-
tion of standard MDR-TB treatment, revealed a 
Beijing strain with mutations conferring resis-
tance to rifampin, isoniazid, ethambutol, ethiona-
mide, fluoroquinolones, pyrazinamide, and strep-
tomycin (Fig. 1). Whole-genome sequencing of 
isolate C, obtained 2 months after treatment 
revision, suggested that there were five poten-
tially effective drugs in the regimen the patient 
had been receiving at the time that bedaquiline 
(to which the isolate was phenotypically suscep-
tible) was added. Targeted deep sequencing of 
isolate C revealed the presence of a base-pair 
insertion in Rv06784 at a variant frequency of 
0.05% (at position 192), indicating microhetero-
resistance (i.e., the presence of resistance-asso-
ciated alleles at a frequency of <1%). This variant 
was not present in isolate B, which had been 
obtained before bedaquiline treatment. Isolate D, 
obtained after bedaquiline cessation, had this 
insertion in more than 90% of the bacterial 
population. The frequency of the insertion in 
Rv0678 at position 192 decreased in subsequent 
isolates, but two different insertions in Rv0678 
emerged (insertion of GA at position 138 in iso-
late F, and insertion of G at position 138 in 
isolate G). The G insertion at position 138 be-
came fixed after all treatment was stopped (iso-
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lates G and H). Isolates D, E, F, G, and H were 
phenotypically resistant to bedaquiline.
This case shows the emergence of bedaquiline 
resistance despite the presence of five poten-
tially effective drugs and good adherence (based 
on clinical notes). The emergence of Rv0678 vari-
ants after completion of 6 months of bedaqui-
line treatment shows the risk of resistance am-
Figure 1. Chronology of Diagnosis and Treatment.
Shown is a summary of treatment, genotypic drug resistance (based on whole-genome sequencing), phenotypic bedaquiline drug-suscep-
tibility testing (DST), targeted deep sequencing, and treatment monitoring during the standard treatment regimen and a subsequent 
 individualized bedaquiline-containing regimen. Overall, eight isolates (A through H) collected between 4.7 months after the initiation of 
the standard regimen and 6 months after all tuberculosis treatment was stopped were analyzed by whole-genome sequencing, targeted 
deep sequencing of Rv0678, and phenotypic bedaquiline DST. The patient was initially given a diagnosis of multidrug-resistant tuber-
culosis (MDR-TB) with low-level isoniazid (INH) resistance, determined with the use of Genotype MTBDRplus, and was treated with a 
standard MDR-TB regimen. However, he remained culture-positive. In accordance with guidelines, subsequent isolates were phenotypi-
cally characterized for susceptibility to ofloxacin (OFX) and amikacin (AMI). Fluoroquinolone resistance (indicated by resistance to OFX) 
was first noted 6 months after treatment initiation. All isolates remained susceptible to second-line injectable antibiotics. At 8.1 months, 
a revised regimen was initiated, with subsequent addition of bedaquiline (BDQ) (22 days after the initiation of the revised regimen) and 
withdrawal of pyrazinamide (Z) and ethambutol (E) (2 months after the initiation of the revised regimen). BDQ was administered for 
6 months. At month 6 of the revised regimen, the patient declined treatment with kanamycin (KAN); he continued to not receive KAN 
for a duration of 2.4 months. Treatment with the individualized regimen was continued until the outcome of treatment failure at 15 months. 
Phenotypic DST showed that all isolates with a variant frequency of more than 1% in Rv0678 were found by mycobacteria growth indica-
tor tube (MGIT) testing to be resistant to BDQ at a concentration of 1 μg per milliliter. ETH denotes ethionamide, LZD linezolid, MXF 
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plification after cessation of treatment with a 
drug that has a long half-life (5.5 months for 
bedaquiline).5
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